Literature DB >> 10797081

High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. Spanish Group for the Study of Infection in the Primary Health Care Setting.

J I Alós1, B Aracil, J Oteo, C Torres, J L Gómez-Garcés.   

Abstract

Using the standard agar dilution method we studied the prevalence of susceptibility to 14-, 15- and 16-membered ring macrolides and clindamycin in Streptococcus pyogenes isolated in 1998 from 21 laboratories in Spain. The number of strains admitted to the study was proportional to the numbers of inhabitants in each geographical area. We also determined the susceptibility phenotypes and the genetic basis for the antibiotic resistance. A total of 486 unduplicated isolates of S. pyogenes were used. Throat swab samples provided 359 (73.9%) isolates, and the remaining 127 isolates were from other sources. One hundred and fourteen (23.5%) isolates were resistant to erythromycin, a 14-membered ring macrolide, and azithromycin, a 15-membered macrolide, whereas only 1% of isolates were resistant to miocamycin, a 16-membered macrolide and 0.8% were resistant to clindamycin. Of the 114 erythromycin-resistant strains, 109 (95.6%) were susceptible to clindamycin and miocamycin. Since induction with erythromycin did not modify susceptibility to the latter antibiotics, these 109 strains were considered to have the M phenotype. Twenty strains with the M phenotype, one per laboratory, were assayed by PCR and showed the presence of the mef gene, which is responsible for antibiotic resistance by an efflux system. Among comparable studies covering entire countries, ours demonstrates one of the highest rates of S. pyogenes erythromycin resistance and clindamycin and miocamycin susceptibility in the world. Strains with the M phenotype account for the great majority of these isolates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797081     DOI: 10.1093/jac/45.5.605

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries.

Authors:  Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Macrolide resistance determinants of invasive and noninvasive group B streptococci in a Turkish hospital.

Authors:  Ziya Cibali Acikgoz; Ebru Almayanlar; Sohret Gamberzade; Safiye Gocer
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 3.  Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E).

Authors:  Corné H W Klaassen; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Association between resistance to erythromycin and the presence of the fibronectin binding protein F1 gene, prtF1, in Streptococcus pyogenes isolates from German pediatric patients.

Authors:  Maria Haller; Kirsten Fluegge; Sandra Jasminder Arri; Brit Adams; Reinhard Berner
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

5.  [Early diagnosis of streptococcal pharyngitis in paediatric practice: Validity of a rapid antigen detection test].

Authors:  Gemma Flores Mateo; Jaume Conejero; Elisabet Grenzner Martinel; Zeki Baba; Susana Dicono; Mildrey Echasabal; Concepción Gonzalo Santos; Arantxa Aliaga; María Barredo; Luis Ruiz; Montserrat Carrau
Journal:  Aten Primaria       Date:  2010-03-26       Impact factor: 1.137

6.  Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.

Authors:  K Nagai; T A Davies; L M Ednie; A Bryskier; E Palavecino; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

7.  Osteomyelitis of the jaw: resistance to clindamycin in patients with prior antibiotics exposure.

Authors:  C Pigrau; B Almirante; D Rodriguez; N Larrosa; S Bescos; G Raspall; A Pahissa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-17       Impact factor: 3.267

8.  Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania.

Authors:  Michael Green; Judith M Martin; Karen A Barbadora; Bernard Beall; Ellen R Wald
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  Molecular epidemiology, antimicrobial susceptibilities and resistance mechanisms of Streptococcus pyogenes isolates resistant to erythromycin and tetracycline in Spain (1994-2006).

Authors:  Virginia Rubio-López; Sylvia Valdezate; David Alvarez; Pilar Villalón; María José Medina; Celia Salcedo; Juan-Antonio Sáez-Nieto
Journal:  BMC Microbiol       Date:  2012-09-21       Impact factor: 3.605

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.